The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Comprehensive molecular portraits of human breast tumours
Open accessAbstract
We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype. We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signalling pathways dominant in each molecular subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype. Comparison of basal-like breast tumours with high-grade serous ovarian tumours showed many molecular commonalities, indicating a related aetiology and similar therapeutic opportunities. The biological finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biological subtypes of breast cancer. The Cancer Genome Atlas Network describe their multifaceted analyses of primary breast cancers, shedding light on breast cancer heterogeneity; although only three genes (TP53, PIK3CA and GATA3) are mutated at a frequency greater than 10% across all breast cancers, numerous subtype-associated and novel mutations were identified. This Article from the Cancer Genome Atlas consortium describes a multifaceted analysis of primary breast cancers in 825 people. Exome sequencing, copy number variation, DNA methylation, messenger RNA arrays, microRNA sequencing and proteomic analyses were performed and integrated to shed light on breast-cancer heterogeneity. Just three genes — TP53, PIK3CA and GATA3 — are mutated at greater than 10% frequency across all breast cancers. Many subtype-associated and novel mutations were identified, as well as two breast-cancer subgroups with specific signalling-pathway signatures. The analyses also suggest that much of the clinically observable plasticity and heterogeneity occurs within, and not across, the major subtypes of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoxia-inducible factor 1α (HIF-1α) is a master transcription factor that is highly expressed in cancer tissues, including breast cancer, and is particularly enriched in triple-negative breast cancer (TNBC)2.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“A recent analysis, combining mutation, mRNA expression and protein levels, determined that the PI3K/Akt pathway was elevated in basal-like cancers as compared with luminal or HER2+ (47).”
From Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer (2014) · cites this paper as [47]
In the citing paper
“In breast cancer, hypoxia is more evident in TNBC than in other breast cancer subtypes11,12.”
In the citing paper
“data analysis of The Cancer Genome Atlas (TCGA) dataset11 identified that hypoxic gene signature, which includes commonly documented hypoxia-responsive genes26, was inversely correlated with immune effector genes (IFNG, TNF, GZMB, PRF1), IFNγ-responsive genes, as well as genes associated with tumor-infiltrating lymphocytes (TILs) in TNBC (n = 99) (also referred as a basal subtype of breast cancer)”
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
In the citing paper
“Analysis of hundreds of triple-negative breast cancers revealed a wide diversity of somatic mutations none of which were found at high frequency [4].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
In the citing paper
“Given the remarkable overexpression of HIF target genes in triple-negative breast cancer [4, 21], the master regulatory role of HIFs in metastasis (Fig. 5), and their involvement in chemotherapy resistance, HIF inhibitors may represent a targeted therapy for these breast cancers.”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J. B., Cronin, M. T., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,321
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,508
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,085
Chen, I. X., Chauhan, V. P., Posada, J., Ng, M. R., Wu, M. W., Adstamongkonkul, P., Huang, P., Lindeman, N., Langer, R., & Jain, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815515116 · Cited by 406
Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer
Budínská, E., Popovici, V. C., Tejpar, S., D’Ario, G., Lapique, N., Sikora, K. O., Narzo, A. F. D., Yan, P., Hodgson, J., Weinrich, S. L., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4212 · Cited by 405
TCGA-Assembler: open-source software for retrieving and processing TCGA data
Zhu, Y., Qiu, P., & Ji, Y. (2014) · Nature Methods · doi:10.1038/nmeth.2956 · Cited by 406
Andersson, A., Larsson, L., Stenbeck, L., Salmén, F., Ehinger, A., Wu, S. Z., Al-Eryani, G., Roden, D., Swarbrick, A., Borg, Å., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26271-2 · Cited by 404
Mechanisms of aromatase inhibitor resistance
Ma, C. X., Reinert, T., Chmielewska, I., & Ellis, M. J. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3920 · Cited by 414
The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death
Zierhut, C., Yamaguchi, N., Paredes, M. C. G., Luo, J., Carroll, T., & Funabiki, H. (2019) · Cell · doi:10.1016/j.cell.2019.05.035 · Cited by 411
Condorelli, R., Spring, L. M., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J. S., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 408
Tumour angiogenesis regulation by the miR-200 family
Pecot, C. V., Rupaimoole, R., Yang, D., Akbani, R., Ivan, C., Lu, C., Wu, S. Y., Han, H., Shah, M., Rodriguez‐Aguayo, C., et al. (2013) · Nature Communications · doi:10.1038/ncomms3427 · Cited by 412
Breast Cancer: Multiple Subtypes within a Tumor?
Yeo, S. K., & Guan, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.09.001 · Cited by 413
Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501605112 · Cited by 398
Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
Beaver, J. A., Jelovac, D., Sasidharan, B., Cochran, R. L., Croessmann, S., Zabransky, D. J., Wong, H. Y., Toro, P. V., Cidado, J. R., Blair, B. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2933 · Cited by 404
ReactomeGSA - Efficient Multi-Omics Comparative Pathway Analysis
Griss, J., Viteri, G., Sidiropoulos, K., Nguyen, V., Fabregat, A., & Hermjakob, H. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir120.002155 · Cited by 418
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Mertins, P., Yang, F., Liu, T., Mani, D. R., Petyuk, V. A., Gillette, M. A., Clauser, K. R., Qiao, J. W., Gritsenko, M. A., Moore, R. J., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036392 · Cited by 400
Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression
Mouw, J. K., Yui, Y., Damiano, L., Bainer, R. O., Lakins, J. N., Acerbi, I., Ou, G., Wijekoon, A. C., Levental, K. R., Gilbert, P. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3497 · Cited by 395
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis
Lefèbvre, C., Bachelot, T., Filleron, T., Pedrero, M., Campone, M., Soria, J., Massard, C., Lévy, C., Arnedos, M., Lacroix‐Triki, M., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002201 · Cited by 398
Triple-negative breast cancer: is there a treatment on the horizon?
Yao, H., He, G., Yan, S., Chen, C., Song, L., Rosol, T. J., & Deng, X. (2016) · Oncotarget · doi:10.18632/oncotarget.12284 · Cited by 394
The shaping and functional consequences of the microRNA landscape in breast cancer
Dvinge, H., Git, A., Gräf, S., Salmon‐Divon, M., Curtis, C. N., Sottoriva, A., Zhao, Y., Hirst, M., Armisen, J., Miska, E. A., et al. (2013) · Nature · doi:10.1038/nature12108 · Cited by 393
Triple-negative breast cancer: treatment challenges and solutions
Jérusalem, G., Collignon, J., Schroeder, H., & Lousberg, L. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s69488 · Cited by 409
Organotropism: new insights into molecular mechanisms of breast cancer metastasis
Chen, W., Hoffmann, A. D., Liu, H., & Liu, X. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0047-0 · Cited by 418
Zill, O. A., Banks, K. C., Fairclough, S. R., Mortimer, S. A., Vowles, J. V., Mokhtari, R., Gandara, D. R., Mack, P. C., Odegaard, J. I., Nagy, R. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3837 · Cited by 391
Schmid, P., Abraham, J., Chan, S. Y. T., Wheatley, D. A., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer
Dong, C., Wu, J., Chen, Y., Nie, J., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.628690 · Cited by 404
Gendoo, D. M. A., Ratanasirigulchai, N., Schröder, M., Paré, L., Parker, J. S., Prat, A., & Haibe‐Kains, B. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv693 · Cited by 389
TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer
de Mingo Pulido, Á., Gardner, A., Hiebler, S., Soliman, H., Rugo, H. S., Krummel, M. F., Coussens, L. M., & Ruffell, B. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.019 · Cited by 388
Menyhárt, O., & Győrffy, B. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.009 · Cited by 412
The Integrated Genomic Landscape of Thymic Epithelial Tumors
Radovich, M., Pickering, C. R., Felau, I., Ha, G., Zhang, H., Jo, H., Hoadley, K. A., Anur, P., Zhang, J., McLellan, M. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.003 · Cited by 392
Frequency and spectrum of PIK3CA somatic mutations in breast cancer
Martínez‐Sáez, O., Chic, N., Pascual, T., Adamo, B., Vidal, M. J., González‐Farré, B., Sanfeliu, E., Schettini, F., Conte, B., Brasó‐Maristany, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01284-9 · Cited by 402
Best practices for variant calling in clinical sequencing
Koboldt, D. C. (2020) · Genome Medicine · doi:10.1186/s13073-020-00791-w · Cited by 415
Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers
Honda, S., Loher, P., Shigematsu, M., Palazzo, J., Suzuki, R., Imoto, I., Rigoutsos, I., & Kirino, Y. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510077112 · Cited by 405
Robidoux, A., Tang, G., Rastogi, P., Geyer, C. E., Azar, C. A., Atkins, J. N., Fehrenbacher, L., Bear, H. D., Baez-Diaz, L., Sarwar, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70411-x · Cited by 392
Barèche, Y., Venet, D., Ignatiadis, M., Aftimos, P. G., Piccart, M. J., Rothé, F., & Sotiriou, C. P. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy024 · Cited by 386
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
Li, S., Garrett-Bakelman, F. E., Chung, S. S., Sanders, M. A., Hricik, T., Rapaport, F., Patel, J. L., Dillon, R. J., Vijay, P., Brown, A. L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4125 · Cited by 396
Hahnen, E., Lederer, B., Hauke, J., Loibl, S., Kröber, S., Schneeweiß, A., Denkert, C., Fasching, P. A., Blohmer, J., Jackisch, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1007 · Cited by 384
The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells
Wang, H., Yu, C. R., Gao, X., Welte, T., Muscarella, A. M., Tian, L. H., Zhao, H., Zhao, Z., Du, S., Tao, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.017 · Cited by 394
Leo, A. D., Johnston, S. R. D., Lee, K. S., Ciruelos, E., Lønning, P. E., Janni, W., O'Regan, R. M., Mouret‐Reynier, M., Kalev, D. N., Egle, D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30688-5 · Cited by 392
Edwards, D. N., Ngwa, V. M., Raybuck, A. L., Wang, S., Hwang, Y., Kim, L. C., Cho, S. H., Paik, Y., Wang, Q., Zhang, S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140100 · Cited by 389
Critical limitations of consensus clustering in class discovery
Şenbabaoğlu, Y., Michailidis, G. C., & Li, J. Z. (2014) · Scientific Reports · doi:10.1038/srep06207 · Cited by 385
Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism
Lee, J., Yesilkanal, A. E., Wynne, J. P., Frankenberger, C. A., Liu, J., Yan, J., Elbaz, M., Rabe, D. C., Rustandy, F. D., Tiwari, P., et al. (2019) · Nature · doi:10.1038/s41586-019-1005-x · Cited by 381
Invasive lobular carcinoma of the breast: morphology, biomarkers and ’omics
Reed, A. E. M., Kutasovic, J. R., Lakhani, S. R., & Simpson, P. T. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0519-x · Cited by 379
Rebouissou, S., Bernard‐Pierrot, I., de Reyniès, A., Lepage, M., Krucker, C., Chapeaublanc, E., Hérault, A., Kamoun, A., Caillault, A., Letouzé, É., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008970 · Cited by 379
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A. A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 385
Lachmann, A., Giorgi, F. M., López, G., & Califano, A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw216 · Cited by 379
Effects of Age on the Detection and Management of Breast Cancer
McGuire, A., Brown, J. A. L., Malone, C. M., McLaughlin, R. P., & Kerin, M. J. (2015) · Cancers · doi:10.3390/cancers7020815 · Cited by 397
The landscape of somatic mutations in Down syndrome–related myeloid disorders
Yoshida, K., Toki, T., Okuno, Y., Kanezaki, R., Shiraishi, Y., Sato‐Otsubo, A., Sanada, M., Park, M.-J., Terui, K., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2759 · Cited by 393
Beaver, J. A., Amiri‐Kordestani, L., Charlab, R., Chen, W., Palmby, T. R., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L. Y., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 380
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Saini, K. S., Loi, S., de Azambuja, E., Metzger, O., Saini, M. L., Ignatiadis, M., Dancey, J. E., & Piccart, M. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.009 · Cited by 384
An update on PARP inhibitors—moving to the adjuvant setting
Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.163 · Cited by 390
Chou, J., Lin, J., Brenot, A., Kim, J., Provot, S., & Werb, Z. (2013) · Nature Cell Biology · doi:10.1038/ncb2672 · Cited by 380
Jiang, Y., Chen, L., Zhang, H., & Xiao, X. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214587 · Cited by 386
HIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer
de Heer, E. C., Jalving, M., & Harris, A. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137552 · Cited by 372
DNA Replication and Oncogene-Induced Replicative Stress
Hills, S. A., & Diffley, J. F. X. (2014) · Current Biology · doi:10.1016/j.cub.2014.04.012 · Cited by 394
Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels
Sobecki, M., Mrouj, K., Colinge, J., Gerbe, F., Jay, P., Krasińska, L., Dulić, V., & Fisher, D. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0707 · Cited by 388
Polyamines in cancer: integrating organismal metabolism and antitumour immunity
Holbert, C. E., Cullen, M., Casero, R. A., & Stewart, T. M. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00473-2 · Cited by 378
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors
Francis, J. M., Kieżun, A., Ramos, A. H., Serra, S., Pedamallu, C. S., Qian, Z. R., Banck, M. S., Kanwar, R., Kulkarni, A. A., Karpathakis, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2821 · Cited by 373
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J. A., Prat, A., Pérez-García, J. M., Adamo, B., Felip, E., Cortés, J., Iafrate, A. J., Nuciforo, P. G., & Tabernero, J. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 378
Principles and methods of integrative genomic analyses in cancer
Kristensen, V. N., Lingjærde, O. C., Russnes, H. G., Vollan, H. K. M., Frigessi, A., & Børresen‐Dale, A. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3721 · Cited by 376
Risom, T., Glass, D. R., Averbukh, I., Liu, C. C., Baranski, A., Kagel, A., McCaffrey, E., Greenwald, N. F., Rivero‐Gutiérrez, B., Strand, S. H., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.023 · Cited by 373
GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibilityPreprint
Theodorou, V., Stark, R., Menon, S., & Carroll, J. S. (2012) · Genome Research · doi:10.1101/gr.139469.112 · Cited by 367
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H. J., Kim, S., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2018) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 376
The role of intratumoral and systemic IL-6 in breast cancer
Dethlefsen, C., Højfeldt, G. W., & Højman, P. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2488-z · Cited by 372
Li, H., Zhu, Y., Burnside, E. S., Huang, E. P., Drukker, K., Hoadley, K. A., Fan, C., Conzen, S. D., Zuley, M. L., Net, J., et al. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.12 · Cited by 363
Tamminga, C. A., Ivleva, E. I., Keshavan, M. S., Pearlson, G. D., Clementz, B. A., Witte, B. P., Morris, D. W., Bishop, J. R., Thaker, G. K., & Sweeney, J. A. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12101339 · Cited by 361
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 369
Ma, C. X., Gao, F., Luo, J. R., Northfelt, D., Goetz, M. P., Forero, A., Hoog, J., Naughton, M., Ademuyiwa, F. O., Suresh, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3206 · Cited by 365
Distinct functions of AKT isoforms in breast cancer: a comprehensive review
Hinz, N., & Jücker, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0450-3 · Cited by 372
27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth
Wu, Q., Ishikawa, T., Sirianni, R., Tang, H., McDonald, J. G., Yuhanna, I. S., Thompson, B. M., Girard, L., Mineo, C., Brekken, R. A., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.006 · Cited by 365
Cell-Cycle Therapeutics Come of Age
Ingham, M. A., & Schwartz, G. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.0032 · Cited by 358
Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis
Sears, C. L., Geis, A. L., & Housseau, F. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72334 · Cited by 362
Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 363
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
Iglesia, M. D., Parker, J. S., Hoadley, K. A., Serody, J. S., Perou, C. M., & Vincent, B. G. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw144 · Cited by 364
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 370
Pappa, K. I., Polyzos, A., Jacob‐Hirsch, J., Amariglio, N., Vlachos, G. D., Loutradis, D., & Anagnou, N. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142229 · Cited by 355
Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling
Luo, M., Li, S., Brooks, M. D., Jiagge, E. M., Zhu, Y., Buschhaus, J. M., Conley, S. J., Fath, M. A., Davis, A., Gheordunescu, E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.006 · Cited by 362
Achieving clinical success with BET inhibitors as anti-cancer agents
Shorstova, T., Foulkes, W. D., & Witcher, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01321-0 · Cited by 367
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Keymeulen, A. V., Lee, M. Y., Ousset, M., Brohée, S., Rorive, S., Giraddi, R. R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I. J., et al. (2015) · Nature · doi:10.1038/nature14665 · Cited by 362
Contribution of p53 to Metastasis
Powell, E., Piwnica-Worms, D. R., & Piwnica-Worms, H. M. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0136 · Cited by 353
Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression
Hu, Q., Ye, Y., Chan, L.-C., Li, Y., Liang, K., Lin, A., Egranov, S. D., Zhang, Y., Xia, W., Gong, J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0400-7 · Cited by 353
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 362
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 355
The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator
Faubert, B., Vincent, E. E., Poffenberger, M. C., & Jones, R. G. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.018 · Cited by 362
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Human breast cancer metastases to the brain display GABAergic properties in the neural niche
Neman, J., Termini, J. S., Wilczynski, S. P., Vaidehi, N., Choy, C., Kowolik, C. M., Li, H., Hambrecht, A. C., Roberts, E., & Jandial, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322098111 · Cited by 348
Gene expression analysis identifies global gene dosage sensitivity in cancer
Fehrmann, R. S. N., Karjalainen, J. M., Krajewska, M., Westra, H.-J., Maloney, D., Simeonov, A., Pers, T. H., Hirschhorn, J. N., Jansen, R. C., Schultes, E. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3173 · Cited by 347
Manahan, E. R., Kuerer, H. M., Sebastian, M., Hughes, K. S., Boughey, J. C., Euhus, D., Boolbol, S. K., & Taylor, W. A. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07549-8 · Cited by 347
Rugo, H. S., Lerebours, F., Ciruelos, E. M., Drullinsky, P. R., Ruíz‐Borrego, M., Neven, P., Park, Y. H., Prat, A., Bachelot, T., Juric, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00034-6 · Cited by 349
Molecular and Cellular Heterogeneity in Breast Cancer
Rivenbark, A. G., O’Connor, S., & Coleman, W. B. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.08.002 · Cited by 365
Widespread intron retention diversifies most cancer transcriptomes
Dvinge, H., & Bradley, R. K. (2015) · Genome Medicine · doi:10.1186/s13073-015-0168-9 · Cited by 372
The neutrophil-to-lymphocyte ratio: a narrative review
Faria, S. S., Fernandes, P. C., Silva, M. J. B., de Lima, V. C. C., Fontes, W., Freitas‐Júnior, R., Eterovic, A. K., & Forget, P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.702 · Cited by 354
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 344
Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors
Paz-Yaacov, N., Bazak, L., Buchumenski, I., Porath, H. T., Danan-Gotthold, M., Knisbacher, B. A., Eisenberg, E., & Levanon, E. Y. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.080 · Cited by 349
Llombart‐Cussac, A., Cortés, J., Paré, L., Galván, P., Bermejo, B., Martínez-Jáñez, N., Vidal, M. J., Pernas, S., López‐López, R., Muñoz-Mateu, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30021-9 · Cited by 346
Computational solutions for omics data
Berger, B., Peng, J., & Singh, M. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3433 · Cited by 353
Henderson, S. R., Chakravarthy, A., Su, X., Boshoff, C., & Fenton, T. R. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.012 · Cited by 345
The future of epigenetic therapy in solid tumours—lessons from the past
Azad, N. S., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 346
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications
Morton, A. R., Dogan-Artun, N., Faber, Z. J., MacLeod, G. D. A. H., Bartels, C. F., Piazza, M. S., Allan, K. C., Mack, S. C., Wang, X., Gimple, R. C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.039 · Cited by 336
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
Xiao, Y., Ma, D., Yang, Y., Yang, F., Ding, J.-H., Gong, Y., Jiang, L., Ge, L., Wu, S., Yu, Q., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00614-0 · Cited by 336
Increased global transcription activity as a mechanism of replication stress in cancer
Kotsantis, P., Silva, L. M., Irmscher, S., Jones, R. M., Folkes, L. K., Gromak, N., & Petermann, E. (2016) · Nature Communications · doi:10.1038/ncomms13087 · Cited by 351
Tung, N., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., Dragun, A. J., Balmañà, J., Hofstatter, E. W., Isaacs, C. J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00299 · Cited by 335
Breast cancer intra-tumor heterogeneity
Martelotto, L. G., Ng, C. K. Y., Piscuoglio, S., Weigelt, B., & Reis-Filho, J. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3658 · Cited by 340
Metadata
- Authors
- The Cancer Genome Atlas Network
- Corresponding author
- The Cancer Genome Atlas Network
- Venue
- Nature
- Published
- 2012-09-23
- Volume
- 490
- Issue
- 7418
- Pages
- 61-70
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3465532
- OpenAlex
- W4301159569
- Cited by
- 12,129
- References
- 56
- Citations by year
- 2026: 552 · 2025: 690 · 2024: 761 · 2023: 781 · 2022: 918 · 2021: 1164 · 2020: 1005 · 2019: 961 · 2018: 942 · 2017: 949 · 2016: 979 · 2015: 909 · 2014: 879 · 2013: 590 · 2012: 40
- FWCI
- 256.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Defense
- Breast Cancer Research Foundation (P50CA116201)
- Henry M. Jackson Foundation
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG004028)
- National Cancer Institute (R01CA094143, U24CA143882, U01CA084955, U24CA143840, U24CA143858, U24CA144025, K08CA148912, U24CA143866, U24CA143883, U24CA143845, U24CA143867, U24CA143848, U24CA143799, U24CA143835, P50 CA 58223, P30CA016672, P30CA016058, P50CA058223, P50CA116201, P30CA016086)
- U.S. National Library of Medicine (R01LM009722)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast cancer, molecular subtypes, tumor heterogeneity, somatic mutations, TP53, PIK3CA, GATA3, MAP3K1, luminal A, HER2-enriched breast cancer, basal-like breast cancer, high-grade serous ovarian cancer, DNA methylation, copy number variation, gene expression signatures, signaling pathways, tumor microenvironment, multi-omics integration
- MeSH terms
- Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Mutation, Ovarian Neoplasms, Receptors, Estrogen, RNA, Messenger, RNA, Neoplasm, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Retinoblastoma Protein, Genes, erbB-2, Genetic Heterogeneity, DNA Methylation, Genes, BRCA1, Phosphatidylinositol 3-Kinases, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Genomics, MicroRNAs, Protein Array Analysis, Proteomics, MAP Kinase Kinase Kinase 1, GATA3 Transcription Factor, Genes, Neoplasm, DNA Copy Number Variations, Class I Phosphatidylinositol 3-Kinases, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
